65 results about "Human immunoglobulins" patented technology

The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

The invention discloses a recombined human hyaluronidase, a production and purification method and preparations of the recombined human hyaluronidase, a use method and application. Recombined human hyaluronidase PH20 or human hyaluronidase human albumin fusion protein PH20-HSA or human hyaluronidase human immunoglobulin IgG2Fc fragment fusion protein PH20-IgFc is adopted by the recombined human hyaluronidase and used in the mucosa or the surface of the skin. The preparations of the recombined human hyaluronidase can be made into different types such as membrane preparations, spray preparations, lotion and freeze-dried powder spray and used for skin infiltration promotion of beauty nutrient substances, skin mucosa infiltration promotion of surface anesthetic, infiltration promotion of skin disease therapeutic medicine, mucosa infiltration promotion of biological tranquillizer, mucosa skin infiltration promotion of growth factors, mucosa infiltration promotion of hypoglycemic drug, mucosa nasal cavity infiltration promotion of nervous centralis nutrient substances and the like.

The invention relates to a liquid pharmaceutical composition comprising human immunoglobulins G (IgGs), comprising at least 200 mM, preferably 250 mM±50 mM, of glycine and between 20 and 100 mg/l of a non-ionic detergent, and having a pH of less than or equal to 4.8.

The invention relates to a preparation process of intravenous injection human immunoglobulin, belonging to the field of pharmaceuticals. On a basis of a traditional preparation process of intravenous injection human immunoglobulin with the low protein concentration of 5 percent, a filter pressing method is adopted instead of a centrifuging method in an extraction process. During hyperfiltration, the protein concentration is adjusted to 3-6 percent, a pH value is adjusted to 6.4-6.6 with 0.5 mol/L of NaOH; then, 1 mol/L phosphoric acid-NaOH buffer solution is added to adjust the electrical conductivity which is measured to be 0.175-0.205 s/m at a temperature T of 19 DEG C; and a chromatography method is adopted to carrying out column chromatography and purification by using upper ion exchange columns after the electrical conductivity is adjusted. The protein impurities can be effectively removed, the protein purify and the product yield are improved; maltose or glycin is used as a protector, which benefits the improvement of the stability of the intravenous injection human immunoglobulin; and the glycin is used as the protector, which satisfies the clinical use of diabetics. According to the invention, the intravenous injection human immunoglobulin with the protein concentration of 5-11 percent can be obtained.

The present invention relates to a method for producing a functional human immunoglobulin, wherein a human heavy chain immunoglobulin, devoid of any light chain, is expressed, comprising the steps of: a) transforming a filamentous host cell with a recombinant construct encoding a modified human heavy chain immunoglobulin, wherein the modifications comprise one or more mutations in the region of the heavy chain protein involved in contact with the light chain; b) culturing said filamentous host cell under conditions promoting expression of said modified human heavy chain immunoglobulin; and c) recovering said modified human heavy chain immunoglobulin.

The invention relates to a human immunoglobulin G composition characterized in that the human immunoglobulin G concentration is at least 230 g/l, which is of use in particular for subcutaneous administration.

The invention discloses hyperglycosylated human growth hormone fusion protein. The human growth hormone fusion protein sequentially contains a human growth hormone (hGH), a flexible peptide joint (L), human chorionic gonadotropin beta-carboxyl terminal rigid peptide (CTP) and a human immunoglobulin Fc fragment from the N terminal to the C terminal. The invention further discloses a method for efficiently preparing the fusion protein. Compared with a recombinant hGH, the built fusion protein has more excellent in-vivo drug efficacy, the in-vivo circulation half-life period is prolonged, the administration frequency is greatly decreased, and the bioavailability is improved; meanwhile, the production process is simpler and more efficient.

Fusion protein RBD-hFc/RBD-His obtained by combining a novel coronavirus (SARS-CoV-2) spike protein receptor binding structural domain (RBD) with a human immunoglobulin hFc domain or His tag through a genetic engineering means is convenient to extract and purify, stable and controllable in quality, short in time consumption and capable of being produced on a large scale. A vaccine composition prepared from the fusion protein and an adjuvant can increase the solubility and stability of a vaccine, enhance the immunogenicity of the vaccine and prolong the half-life period of the vaccine in vivo. The fusion protein and the vaccine composition thereof can inhibit replication and transmission of SARS-CoV-2 wild type and/or variant strains or prevent the SARS-CoV-2 wild type and/or variant strains from settling in a host, so that novel coronavirus pneumonia caused by the SARS-CoV-2 wild type and/or variant strains can be effectively prevented and/or treated.

The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

The invention relates inter alia to a method of treating tumorous disease in a human patient by administering to the patient a human immunoglobulin specifically binding to the human EpCAM antigen, the immunoglobulin exhibiting a serum half-life of at least 15 days, the method comprising the step of administering the immunoglobulin no more frequently than once every week, preferably no more frequently than once every two weeks.

The invention, which belongs to the technical field of medical in-vitro diagnostics, relates to a human urine immunoglobulin G detection kit based on latex-enhanced immunoturbidimetry, thereby solvinga problem of providing a human urine immunoglobulin G content detection kit having advantages of wide detection linear range, high detection accuracy, and high detection stability. The kit comprisesan R1 reagent, an R2 reagent and a calibrator. The R1 reagent includes a buffer solution, NaCl and a preservative. The R2 reagent includes a buffer solution, an antibody-coupling latex microsphere, aprotective agent and a preservative; and the antibody is the goat anti-human immunoglobulin polyclonal antibody or a rabbit anti-human immunoglobulin polyclonal antibody. The calibrator is formed by aplurality of solution; each solution includes human immunoglobulin G, a buffer solution and a preservative; and the concentrations of the human immunoglobulin G in different solutions are different.The kit has advantages of wide detection linear range, high detection accuracy, and high detection stability.

The present invention belongs to the field of biotechnology, and relates to a surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment, encoded gene and use thereof. According to the invention, the surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is filtered from a base through establishing a Toxoplasma gondii human immunoglobulin, ELISA, diluting the prothrombin time, sequencing analysis, etc. Through expression purifying and authenticating, the human antigen Fab fragment is authenticated to specifically identify the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii and have higher affinity with the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii, for being identified with the specificity of Toxoplasma gondii tachyzoite-bradyzoite. The human antigen Fab fragment of the invention does not contain Fc segment and does not activate the alexin or cause the histopathological damages of human immune response, etc. when the function of restricting the invasion of Toxoplasma gondii to the host cell is exerted. The surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is safe and reliable when applied for the human body. The antigen medicine for treating toxoplasmosis or the antigen targeted medicine can be prepared.

The present invention describes the composition of class and subclass selected pooled human immunoglobulins with catalytic activity, methods of preparation thereof, and therapeutic utility thereof.

The invention belongs to the field of biological products, in particular to a new application of the existing product-rabies human immunoglobulin. The technical proposal of the invention is the new application of rabies human immunoglobulin in preparing medicine for preventing and controlling Japanese encephalitis. The invention also provides a combined vaccine for rabies and Japanese encephalitis. The vaccine of the invention has better effect than conventional Japanese encephalitis vaccine in preventing and controlling Japanese encephalitis and fundamental immunity for resisting the rabies virus is obtained. The combined vaccine features scientific immunization schedule, few times of vaccine inoculation, easy promotion of inoculation and good effect in boostering immunization in case of emergency in preventing and controlling the rabies. The antibody and the vaccine jointly solve the technical and application problems of preventing and controlling the Japanese encephalitis and the rabies, thus enjoying great social and economic significance.

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 Å as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

Complexes are described that form in vitro following incubation of “Heat Shock Protein” (HSP) “Glucose-regulated Protein” 94 (Grp94) with human non-immune immunoglobulin G. Results show that complexes of Grp94-IgG are resistant to denaturing agents. Moreover, complexes display an important cytokine-like property that can be exploited to induce positive effects of immuno-modulation in pathologies characterized by either a reduced or exacerbated immune response. In addition, stability of Grp94-IgG complexes make them useful as diagnostic tools to detect antibodies directed against Grp94 in various pathological conditions.

The invention provides a T lymphocyte of a chimeric chondroitin sulfate proteoglycan 4 receptor. The T lymphocyte comprises an extracellular domain structure, a human CD28 transmembrane sequence and an intracellular domain structure, wherein the extracellular domain structure is formed by sequentially connecting a signal peptide sequence, an optimized CSPG4 single-chain antibody sequence and a sequence with a human immunoglobulin G2 mutation sequence as a hinge region in series; a genetic sequence of the optimized CSPG4 single-chain antibody is as shown in any one of SEQ ID NO.33-42; a geneticsequence of the hinge region is as shown in SEQ ID NO.31; and the intracellular domain structure is formed by connecting a human CD28 or 41BB intracellular domain costimulatory domain sequence and ahuman CD3[zeta] intracellular domain sequence in series. The invention also provides a preparation method of the T lymphocyte of the chimeric chondroitin sulfate proteoglycan 4 receptor. Meanwhile, the invention provides an application of the T lymphocyte in preparation of drugs for treatment of head and neck tumors. The optimized CSPG4.CAR-T cell can be used for effectively killing the CSPG4 positive tumor cells in vitro and vivo.

A method and apparatus for the differentiation of ulcerative colitis from Crohn's disease and other gastrointestinal illnesses using the presence of anti-neutrophil cytoplasmic antibodies (ANCA) as a marker of ulcerative colitis is described. The apparatus consists of either a qualitative enzyme-linked immunoassay or other immunoassay that utilizes antibodies specific to human immunoglobulins for the measurement of total endogenous ANCA in a human sample. The method and apparatus can be used by healthcare providers to distinguish ulcerative colitis from Crohn's disease and other gastrointestinal illnesses.